• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高剂量放射治疗体积精化治疗喉癌患者的临床结果。

Clinical outcomes for larynx patients with cancer treated with refinement of high-dose radiation treatment volumes.

机构信息

Department of Human Oncology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Department of Surgery, Division of Otolaryngology and Head and Neck Surgery, Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

出版信息

Head Neck. 2020 Aug;42(8):1874-1881. doi: 10.1002/hed.26098. Epub 2020 Feb 14.

DOI:10.1002/hed.26098
Abstract

BACKGROUND

To evaluate disease control, toxicities, and dose to dysphagia/aspiration risk structures (DARS) using a direct gross tumor volume (GTV ) to planning target volume expansion (dPTV ) for patients with squamous cell carcinoma of the larynx (LSCC).

METHODS

A retrospective review was performed on patients with LSCC treated between 2003 and 2018. Clinical outcomes, toxicities, and dosimetric data were analyzed.

RESULTS

Seventy-three patients were identified. Overall survival at 5-years was 57.8%. Five-year local and regional control was 79.8% and 88.2%, respectively. Distant metastatic-only failure was 2.7%. Eighty percent of failures were 95% contained within the dPTV . Mean dose and the volume of DARS receiving 70 Gy was significantly lower for dPTV compared to a consensus-defined PTV .

DISCUSSION

Judicious reduction in high-dose target volumes can preserve high tumor control rates while reducing dose to normal surrounding structures underscoring the potential benefit of this approach in enabling local therapy intensification to improve locoregional control.

摘要

背景

评估使用直接大体肿瘤体积(GTV)至计划靶区外扩(dPTV)的方法治疗喉鳞状细胞癌(LSCC)患者的疾病控制、毒性和吞咽/吸入风险结构(DARS)剂量。

方法

对 2003 年至 2018 年间治疗的 LSCC 患者进行回顾性研究。分析临床结果、毒性和剂量学数据。

结果

共确定了 73 例患者。5 年总生存率为 57.8%。5 年局部控制率和区域控制率分别为 79.8%和 88.2%。远处转移失败仅为 2.7%。80%的失败病例 95%的体积包含在 dPTV 内。与共识定义的 PTV 相比,dPTV 的平均剂量和 DARS 体积接受 70Gy 的剂量明显更低。

讨论

明智地减少高剂量靶区体积可以在降低正常周围结构剂量的同时保持高肿瘤控制率,这突显了这种方法的潜在益处,即能够加强局部治疗以提高局部区域控制率。

相似文献

1
Clinical outcomes for larynx patients with cancer treated with refinement of high-dose radiation treatment volumes.高剂量放射治疗体积精化治疗喉癌患者的临床结果。
Head Neck. 2020 Aug;42(8):1874-1881. doi: 10.1002/hed.26098. Epub 2020 Feb 14.
2
Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.头颈部鳞状细胞癌的调强放射治疗——爱荷华大学的经验
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21. doi: 10.1016/j.ijrobp.2005.02.025.
3
[Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma].局部区域晚期鼻咽癌的调强放射治疗
Ai Zheng. 2004 Nov;23(11 Suppl):1532-7.
4
Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.同步整合加量调强放射治疗局部晚期头颈部鳞状细胞癌:II期临床结果
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):374-87. doi: 10.1016/j.ijrobp.2004.03.010.
5
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.放射治疗肿瘤学组(RTOG)9311的毒性反应和结果:一项针对无法手术的非小细胞肺癌患者采用三维适形放疗的I-II期剂量递增研究。
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28. doi: 10.1016/j.ijrobp.2004.06.260.
6
Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.局部晚期(II期及更严重)头颈癌的三维适形放疗:剂量学和临床评估
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1036-43. doi: 10.1016/j.ijrobp.2006.03.014. Epub 2006 Jun 5.
7
Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.使用多叶准直器束对非小细胞肺癌进行多野适形放射治疗的结果。
Radiat Oncol Investig. 1999;7(5):297-308. doi: 10.1002/(SICI)1520-6823(1999)7:5<297::AID-ROI5>3.0.CO;2-Z.
8
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.喉剂量可预测调强放疗后的吞咽并发症。
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8. doi: 10.1016/j.ijrobp.2008.02.048. Epub 2008 May 28.
9
Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume.口咽癌的调强放射治疗:肿瘤体积的影响
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):43-50. doi: 10.1016/j.ijrobp.2003.08.004.
10
Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh.大腿软组织肉瘤的调强放射治疗
Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):752-9. doi: 10.1016/j.ijrobp.2003.11.037.

引用本文的文献

1
Patterns of failure for hypopharynx cancer patients treated with limited high-dose radiotherapy treatment volumes.接受有限高剂量放疗治疗体积的下咽癌患者的失败模式。
Radiat Oncol J. 2022 Dec;40(4):225-231. doi: 10.3857/roj.2022.00311. Epub 2022 Dec 2.
2
Defining high-risk elective contralateral neck radiation volumes for oropharynx cancer.定义口咽癌高风险选择性对侧颈部放疗靶区。
Head Neck. 2022 Feb;44(2):317-324. doi: 10.1002/hed.26924. Epub 2021 Nov 11.

本文引用的文献

1
Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer.减少 HPV 相关口咽癌患者的放射治疗靶区扩张。
Oral Oncol. 2019 May;92:52-56. doi: 10.1016/j.oraloncology.2019.03.013. Epub 2019 Mar 22.
2
Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.低危型人乳头瘤病毒相关口咽鳞状细胞癌去强化放化疗的前瞻性研究的成熟结果。
Cancer. 2018 Jun 1;124(11):2347-2354. doi: 10.1002/cncr.31338. Epub 2018 Mar 26.
3
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.
喉、下咽、口咽和口腔鳞状细胞癌的原发肿瘤临床靶区(CTV-P)勾画:AIRO、CACA、DAHANCA、EORTC、GEORCC、GORTEC、HKNPCSG、HNCIG、IAG-KHT、LPRHHT、NCIC CTG、NCRI、NRG Oncology、PHNS、SBRT、SOMERA、SRO、SSHNO、TROG 共识指南。
Radiother Oncol. 2018 Jan;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016. Epub 2017 Nov 24.
4
Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx.声门型喉T3N0M0鳞状细胞癌患者的生存结果
JAMA Otolaryngol Head Neck Surg. 2017 Nov 1;143(11):1126-1133. doi: 10.1001/jamaoto.2017.1756.
5
Laryngeal tumours and radiotherapy dose to the cricopharyngeus are predictive of death from aspiration pneumonia.喉肿瘤以及环咽肌的放疗剂量可预测吸入性肺炎导致的死亡。
Oral Oncol. 2017 Jan;64:9-14. doi: 10.1016/j.oraloncology.2016.11.010. Epub 2016 Nov 29.
6
Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications.调强放射治疗时代失败模式的分析与报告方法:头颈部癌应用
Radiat Oncol. 2016 Jul 26;11(1):95. doi: 10.1186/s13014-016-0678-7.
7
Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.西妥昔单抗与放疗用于喉癌和下咽癌的喉功能保留:一项随机临床试验的二次分析
JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):842-9. doi: 10.1001/jamaoto.2016.1228.
8
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.诱导化疗联合顺铂、5-氟尿嘧啶、±多西他赛用于喉保留的多中心随机 III 期试验的长期结果。
J Natl Cancer Inst. 2015 Dec 16;108(4). doi: 10.1093/jnci/djv368. Print 2016 Apr.
9
Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes.T4a期喉癌的全喉切除术与喉保留术:治疗模式与生存结果
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):594-601. doi: 10.1016/j.ijrobp.2015.03.004.
10
Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer.头颈部癌同步放化疗后吸入性肺炎
Cancer. 2015 Apr 15;121(8):1303-11. doi: 10.1002/cncr.29207. Epub 2014 Dec 23.